Loxone-400 (Tablets) Instructions for Use
Marketing Authorization Holder
Micro Labs Limited (India)
ATC Code
J01MA06 (Norfloxacin)
Active Substance
Norfloxacin (Rec.INN registered by WHO)
Dosage Form
| Loxone-400 | Film-coated tablets, 400 mg: 10 or 100 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets orange in color, oval, biconvex, with a score on one side.
| 1 tab. | |
| Norfloxacin | 400 mg |
Excipients: microcrystalline cellulose, corn starch, colloidal silicon dioxide, methylparaben, propylparaben, purified talc, magnesium stearate, purified water.
Film coating composition: hypromellose, Tabcoat TS-0-2003 orange (the composition of this ingredient includes titanium dioxide and sunset yellow dye), propylene glycol, purified talc.
10 pcs. – blisters (1) – cardboard packs.
10 pcs. – blisters (10) – cardboard packs.
Clinical-Pharmacological Group
Antibacterial drug of the fluoroquinolone group
Pharmacotherapeutic Group
Antimicrobial agent – fluoroquinolone
Pharmacological Action
A broad-spectrum antimicrobial synthetic agent of the fluoroquinolone group. It has a bactericidal effect. By suppressing DNA gyrase, it disrupts the DNA supercoiling process.
It is highly active against most gram-negative bacteria: Escherichia coli, Salmonella spp., Shigella spp., Proteus spp., Morganella morganii, Klebsiella spp. (including Klebsiella pneumoniae), Enterobacter spp., Serratia spp., Citrobacter spp., Yersinia spp., Providencia spp., Haemophilus influenzae, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Neisseria meningitidis.
It is active against some gram-positive bacteria (including Staphylococcus aureus).
Anaerobic bacteria are resistant to norfloxacin, while Enterococcus spp. and Acinetobacter spp. are poorly sensitive.
It is resistant to the action of β-lactamases.
Pharmacokinetics
When taken orally, approximately 30-40% is absorbed; food intake reduces the rate of absorption. Plasma protein binding is 14%. Norfloxacin is well distributed in the tissues of the urogenital system. It crosses the placental barrier. About 30% is excreted unchanged in the urine.
Indications
Infectious and inflammatory diseases caused by microorganisms sensitive to norfloxacin, including diseases of the urinary tract, prostate gland, gastrointestinal tract, gonorrhea, prevention of recurrences of urinary tract infections, bacterial infections in patients with granulocytopenia, “traveler’s diarrhea”.
ICD codes
| ICD-10 code | Indication |
| A09 | Other and unspecified gastroenteritis and colitis of infectious origin |
| A54 | Gonococcal infection |
| K81.0 | Acute cholecystitis |
| K81.1 | Chronic cholecystitis |
| K83.0 | Cholangitis |
| N10 | Acute tubulointerstitial nephritis (acute pyelonephritis) |
| N11 | Chronic tubulointerstitial nephritis (chronic pyelonephritis) |
| N30 | Cystitis |
| N34 | Urethritis and urethral syndrome |
| N41 | Inflammatory diseases of prostate |
| N74.3 | Gonococcal inflammatory diseases of female pelvic organs |
| N77.1 | Vaginitis, vulvitis and vulvovaginitis in infectious and parasitic diseases classified elsewhere |
| Z29.2 | Other prophylactic chemotherapy (administration of antibiotics for prophylactic purposes) |
| ICD-11 code | Indication |
| 1A40.Z | Infectious gastroenteritis or colitis, unspecified |
| 1A7Z | Gonococcal infection, unspecified |
| 1F23.10 | Candidiasis of vulva and vagina |
| 1F65 | Enterobiasis |
| 1H0Z | Unspecified infection |
| DC12.0Z | Acute cholecystitis, unspecified |
| DC12.1 | Chronic cholecystitis |
| DC13 | Cholangitis |
| GA91.Z | Inflammatory and other diseases of prostate, unspecified |
| GB50 | Acute tubulo-interstitial nephritis |
| GB51 | Acute pyelonephritis |
| GB55.Z | Chronic tubulo-interstitial nephritis, unspecified |
| GB5Z | Renal tubulo-interstitial diseases, unspecified |
| GC00.Z | Cystitis, unspecified |
| GC02.Z | Urethritis and urethral syndrome, unspecified |
| QC05.Y | Other specified prophylactic measures |
| 1A71 | Gonococcal pelviperitonitis |
| GA05.Z | Inflammatory diseases of female pelvic organs, unspecified |
| 1A94.0 | Genital or urogenital tract infection caused by Herpes simplex virus |
| GA41 | Ulcerative or erosive diseases of vulva |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Determine the dosage individually based on the type and severity of the infection.
For uncomplicated urinary tract infections, take 400 mg orally twice daily for 7 to 10 days.
For complicated urinary tract infections, take 400 mg orally twice daily for 10 to 21 days.
For prostatitis, take 400 mg orally twice daily for 28 days.
For gonorrhea, administer a single 800 mg dose.
For gastrointestinal infections such as “traveler’s diarrhea”, take 400 mg orally twice daily for 3 to 5 days.
For prophylaxis of recurrent urinary tract infections, take 200 mg once daily at bedtime.
For patients with renal impairment, adjust the dose if creatinine clearance is below 30 mL/min; a recommended regimen is 400 mg once daily.
Take tablets with a full glass of water, at least 2 hours before or 2 hours after consuming antacids or products containing magnesium, aluminum, iron, zinc, or calcium.
Complete the entire prescribed course of therapy, even if symptoms improve.
Adverse Reactions
From the digestive system: nausea, heartburn, anorexia, diarrhea, abdominal pain.
From the CNS: headache, dizziness, feeling of fatigue, sleep disorders, irritability, feeling of anxiety.
Allergic reactions: skin rash, itching, angioedema.
From the urinary system: interstitial nephritis.
Contraindications
Pregnancy, lactation (breastfeeding), childhood and adolescence (up to 15 years), glucose-6-phosphate dehydrogenase deficiency, hypersensitivity to norfloxacin and other quinolone drugs.
Use in Pregnancy and Lactation
Norfloxacin is contraindicated during pregnancy and lactation (breastfeeding), since experimental studies have established that it causes arthropathy.
Use in Hepatic Impairment
Should be used with caution in patients with severe liver function impairment.
Use in Renal Impairment
Should be used with caution in patients with severe renal function impairment.
Pediatric Use
Contraindicated in childhood and adolescence (up to 15 years).
Special Precautions
Should be used with caution in patients with epilepsy, convulsive syndrome of other etiology, and with severe impairment of renal and liver function. During treatment, patients should receive a sufficient amount of fluid (under diuresis control).
Norfloxacin should be taken no less than 2 hours before or 2 hours after taking antacids or preparations containing iron, zinc, magnesium, calcium, or sucralfate.
Drug Interactions
With simultaneous use of norfloxacin with warfarin, the anticoagulant effect of the latter is enhanced.
With simultaneous use of norfloxacin with cyclosporine, an increase in the concentration of the latter in blood plasma is noted.
With simultaneous administration of norfloxacin and antacids or preparations containing iron, zinc, magnesium, calcium, or sucralfate, the absorption of norfloxacin is reduced due to the formation of chelates with metal ions (the interval between their intake should be at least 4 hours).
With simultaneous administration, Norfloxacin reduces the clearance of theophylline by 25%, therefore, when used concomitantly, the dose of theophylline should be reduced.
Simultaneous administration of norfloxacin with drugs that have a potential ability to reduce blood pressure may cause a sharp decrease in it. In this regard, in such cases, as well as with simultaneous administration of barbiturates and anesthetic agents, heart rate, blood pressure, and ECG parameters should be monitored. Simultaneous use with drugs that lower the epileptic threshold may lead to the development of epileptiform seizures.
It reduces the effect of nitrofurans.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer